SK1012001A3 - Use of glucose uptake enhancer for reducing apoptosis - Google Patents

Use of glucose uptake enhancer for reducing apoptosis Download PDF

Info

Publication number
SK1012001A3
SK1012001A3 SK101-2001A SK1012001A SK1012001A3 SK 1012001 A3 SK1012001 A3 SK 1012001A3 SK 1012001 A SK1012001 A SK 1012001A SK 1012001 A3 SK1012001 A3 SK 1012001A3
Authority
SK
Slovakia
Prior art keywords
compound
absorption enhancer
glucose absorption
thiazolidinedione
mammal
Prior art date
Application number
SK101-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Antoine Michel Alain Bril
Robin Edwin Buckingham
Nassirah Khandoudi
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815871.0A external-priority patent/GB9815871D0/en
Priority claimed from GBGB9815872.8A external-priority patent/GB9815872D0/en
Priority claimed from GBGB9905387.8A external-priority patent/GB9905387D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Lab filed Critical Smithkline Beecham Plc
Publication of SK1012001A3 publication Critical patent/SK1012001A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SK101-2001A 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing apoptosis SK1012001A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9815871.0A GB9815871D0 (en) 1998-07-21 1998-07-21 Novel compound
GBGB9815872.8A GB9815872D0 (en) 1998-07-21 1998-07-21 Novel method
GBGB9905387.8A GB9905387D0 (en) 1999-03-09 1999-03-09 Novel method
PCT/GB1999/002361 WO2000004890A1 (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing apoptosis

Publications (1)

Publication Number Publication Date
SK1012001A3 true SK1012001A3 (en) 2001-08-06

Family

ID=27269407

Family Applications (1)

Application Number Title Priority Date Filing Date
SK101-2001A SK1012001A3 (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing apoptosis

Country Status (26)

Country Link
EP (2) EP1516617A2 (de)
JP (1) JP2002521326A (de)
KR (1) KR20010079551A (de)
CN (1) CN1310620A (de)
AP (1) AP2001002036A0 (de)
AT (1) ATE288746T1 (de)
AU (1) AU5053799A (de)
BG (1) BG105250A (de)
BR (1) BR9912117A (de)
CA (1) CA2338211A1 (de)
DE (1) DE69923687T2 (de)
DK (1) DK1098639T3 (de)
EA (1) EA200100165A1 (de)
ES (1) ES2237929T3 (de)
HK (1) HK1037865A1 (de)
HU (1) HUP0103199A3 (de)
ID (1) ID26986A (de)
IL (1) IL140664A0 (de)
NO (1) NO20010292L (de)
OA (1) OA11579A (de)
PL (1) PL345627A1 (de)
PT (1) PT1098639E (de)
SI (1) SI1098639T1 (de)
SK (1) SK1012001A3 (de)
TR (1) TR200100207T2 (de)
WO (1) WO2000004890A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043007A1 (fr) * 1999-01-19 2000-07-27 Sankyo Company, Limited Compositions médicinales à base de troglitazone inhibitrices de l'apoptose
ES2204684T3 (es) * 1999-08-27 2004-05-01 Eli Lilly And Company Derivados de biaril-oxa(tia)zol y su uso como modulares de ppar.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (de) * 1987-09-04 1998-05-20 Beecham Group Plc Substituierte Thiazolidindionderivate
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
IL120443A (en) * 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
HUP0002941A3 (en) * 1996-09-12 2001-11-28 Sankyo Company Ltd Chuo Ku Glutathione reductase activity potentiator containing troglitazone
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
WO1999025346A1 (en) * 1997-11-19 1999-05-27 Takeda Chemical Industries, Ltd. Novel apoptosis inhibitors
WO1999043326A1 (en) * 1998-02-24 1999-09-02 The Trustees Of The University Of Pennsylvania Use of a cardiac purinoceptor to effect cellular glucose uptake
AU4005299A (en) * 1998-05-19 1999-12-06 Regents Of The University Of California, The Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism

Also Published As

Publication number Publication date
SI1098639T1 (de) 2005-08-31
NO20010292D0 (no) 2001-01-18
EA200100165A1 (ru) 2001-08-27
CN1310620A (zh) 2001-08-29
ES2237929T3 (es) 2005-08-01
EP1098639A1 (de) 2001-05-16
PL345627A1 (en) 2002-01-02
BG105250A (en) 2001-11-30
HK1037865A1 (en) 2002-02-22
AU5053799A (en) 2000-02-14
BR9912117A (pt) 2001-04-10
DE69923687D1 (de) 2005-03-17
DK1098639T3 (da) 2005-06-13
EP1098639B1 (de) 2005-02-09
WO2000004890A1 (en) 2000-02-03
ID26986A (id) 2001-02-22
DE69923687T2 (de) 2006-04-06
PT1098639E (pt) 2005-06-30
OA11579A (en) 2004-06-01
AP2001002036A0 (en) 2001-03-31
IL140664A0 (en) 2002-02-10
HUP0103199A2 (hu) 2002-05-29
KR20010079551A (ko) 2001-08-22
CA2338211A1 (en) 2000-02-03
EP1516617A2 (de) 2005-03-23
NO20010292L (no) 2001-03-08
JP2002521326A (ja) 2002-07-16
TR200100207T2 (tr) 2001-05-21
ATE288746T1 (de) 2005-02-15
HUP0103199A3 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
US6613785B2 (en) Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
SK179299A3 (en) Use of insulin sensitiser and a biguanide antihyperglycaemic agent
KR100671918B1 (ko) 티아졸리딘디온, 인슐린 분비촉진제 및 디구아니드를사용한 당뇨병의 치료
SK1022001A3 (en) USE OF GLUCOSE UPTAKE ENHANCER FOR REDUCING POST-ISCHEMIC INJURYì (54) OF THE HEART
SK1012001A3 (en) Use of glucose uptake enhancer for reducing apoptosis
SK612000A3 (en) Application of insulin sensitiser, insulin secretagogue and alpha glucosidase inhibitor antihyperglycaemic agent for the treatment of diabetes mellitus and conditions associated with diabetes mellitus and a pharmaceutical composition
SK179499A3 (en) The use of insulin sensitiser and alpha-glucosidase inhibitive antihyperglycaemic agent
PL199125B1 (pl) Kompozycja farmaceutyczna zawierająca tiazolidynodion i sulfonylomocznik oraz jej zastosowanie
US20040254229A1 (en) Use of glucose uptake enhancer for reducing apoptosis
CZ299801B6 (cs) Farmaceutický prostredek s postupným uvolnováním a lécivo pro lécení diabetes mellitus typu 2 a stavu souvisejících s diabetes mellitus
SK5322000A3 (en) Use of thiazolidinediones for the treatment of hyperglycaemia
ZA200100438B (en) Use of glucose uptake enhancer for reducing apoptosis.
AU2005202209A1 (en) Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
CZ20024067A3 (cs) Léčivo pro léčení nebo profylaxi srdeční rezistence na insulin
BG104404A (bg) Използване на тиазолидиндиони за лечение на хипергликемия
MXPA00003634A (en) Use of thiazolidinediones for the treatment of hyperglycaemia
MXPA00003633A (en) Use of thiazolidinediones for the treatment of hyperglycaemia
CZ2000174A3 (cs) Farmaceutický prostředek proti diabetů mellitus a stavům s ním spojeným
UA68352C2 (en) Method for treatment of diabetes mellitus with thiazolidin and metformin